Pluristem Therapeutics Inc. (PSTI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pluristem Therapeutics Inc. (PSTI) Healthcare & Pipeline Overview

Pluristem Therapeutics Inc., an Israel-based biotechnology firm, specializes in placental expanded (PLX) cell therapies targeting a range of conditions including ischemia, inflammation, and autoimmune disorders. With clinical trials underway, Pluristem aims to leverage its proprietary technology in the competitive biotechnology landscape.

What Is the Investment Thesis for PSTI?

Pluristem Therapeutics operates in the high-risk, high-reward biotechnology sector. The company's PLX-PAD Phase III trial for hip fracture recovery represents a near-term catalyst, while ongoing Phase II and Phase I/II trials address significant unmet medical needs. Success in these trials could drive substantial value. The company's negative profit margin of -723.4% and a P/E ratio of -8.95 highlight its pre-profitability status, typical for biotechnology firms heavily invested in R&D. Investors should closely monitor clinical trial outcomes and regulatory milestones. The company's beta of 1.91 indicates higher volatility compared to the overall market.

Based on FMP financials and quantitative analysis

PSTI Key Highlights

Market capitalization of $40.9M indicates a small-cap company with potential for growth but also higher risk.

• Gross margin of 35.6% suggests a reasonable level of efficiency in converting revenue into gross profit, though this needs to be balanced against high operating expenses typical of biotech companies.
• Phase III clinical trial for PLX-PAD in hip fracture recovery represents a near-term value driver.
• Collaboration with NASA's Ames Research Center provides potential for long-term growth and diversification.
• Negative profit margin of -723.4% reflects the company's focus on R&D and clinical trials, indicating a need for successful product commercialization.

Who Are PSTI's Competitors?

PSTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PSTI's Key Strengths?

Proprietary PLX cell therapy technology platform.

• Diverse pipeline of clinical trials targeting multiple indications.
• Collaboration agreements with reputable organizations like NASA.
• Experienced management team with expertise in cell therapy development.

What Are PSTI's Weaknesses?

Negative profit margin and reliance on external funding.

• High R&D costs and lengthy regulatory approval processes.
• Small market capitalization and limited financial resources.
• Concentration of pipeline on PLX technology, creating potential risk.

What Could Drive PSTI Stock Higher?

PSTI catalyst: Results from the Phase III clinical trial of PLX-PAD for hip fracture recovery are expected in late 2026.

• Data readout from the Phase II clinical trial of PLX-PAD for ARDS associated with COVID-19 is anticipated in Q4 2026.
• Continued progress in the Phase I/II clinical trial of PLX-PAD for steroid-refractory graft versus host disease.
• Advancements in animal studies evaluating PLX-R18 for the treatment of acute radiation syndrome.
• Further developments in the collaboration with NASA's Ames Research Center to evaluate PLX cell therapies for space-related medical conditions.

What Are the Key Risks for PSTI?

Financial-distress signal — its Altman Z-Score of -42.91 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures could significantly impact the company's valuation.
• Regulatory delays or rejections could hinder product commercialization.
• Competition from other biotechnology companies developing cell-based therapies.
• Dependence on external funding to support R&D activities.
• Intellectual property disputes could threaten the company's competitive advantage.

What Are the Growth Opportunities for PSTI?

• PLX-PAD for Hip Fracture Recovery: Pluristem's Phase III clinical trial for PLX-PAD in hip fracture recovery represents a significant near-term growth opportunity. The market for post-surgical recovery therapies is substantial, driven by an aging population and increasing incidence of hip fractures. Successful completion of the trial and subsequent regulatory approval could lead to significant revenue generation. The timeline for potential commercialization is dependent on trial outcomes and regulatory review, but could be within the next 2-3 years.
• PLX-PAD for ARDS Associated with COVID-19: The Phase II clinical trial of PLX-PAD for acute respiratory distress syndrome (ARDS) associated with COVID-19 presents a growth opportunity. While the pandemic's acute phase has subsided, ARDS remains a significant complication for some patients. Positive results could position PLX-PAD as a valuable treatment option. The timeline for potential commercialization depends on trial outcomes and regulatory pathways, potentially within 2-4 years.
• PLX-R18 for Hematopoietic Recovery: Pluristem's development of PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation offers a growth avenue. This therapy targets a niche market within the broader transplantation field. Positive Phase I trial results provide a foundation for further development. The timeline for potential commercialization is longer, potentially 4-6 years, as it requires further clinical trials and regulatory approvals.
• Collaboration with NASA: Pluristem's collaboration with NASA's Ames Research Center to evaluate PLX cell therapies for space-related medical conditions represents a long-term growth opportunity. While the space tourism and exploration market is still developing, it presents a unique application for cell therapies. This collaboration could lead to novel applications and intellectual property. The timeline for commercialization is uncertain, potentially 5-10 years or more.
• Expansion into New Therapeutic Areas: Pluristem has the potential to expand its PLX technology into new therapeutic areas beyond its current focus. This could involve exploring applications in other inflammatory conditions, autoimmune disorders, or ischemic diseases. This strategy would require further research and development, but could significantly broaden the company's market reach. The timeline for potential expansion is dependent on research progress and strategic decisions, potentially 3-5 years.

What Threats Does PSTI Face?

• Competition from other biotechnology companies.
• Clinical trial failures and regulatory setbacks.
• Changes in healthcare regulations and reimbursement policies.
• Economic downturn and reduced access to funding.

What Are PSTI's Competitive Advantages?

• Proprietary PLX cell therapy technology.
• Clinical trial data and regulatory approvals.
• Collaborations with leading research institutions.
• Intellectual property protection through patents.

What Does PSTI Do?

Pluristem Therapeutics Inc., established in 2001 and headquartered in Haifa, Israel, is a biotechnology company dedicated to the research, development, clinical trial, and manufacturing of cell therapeutic products and related technologies. The company focuses on addressing various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. Pluristem's core technology revolves around placental expanded (PLX) cells, a proprietary platform for developing cell therapies. Its lead product candidate, PLX-PAD, is undergoing a Phase III clinical trial for recovery after hip fracture surgery. Additionally, PLX-PAD is in Phase II clinical trials for acute respiratory distress syndrome (ARDS) associated with COVID-19 and in Phase I/II trials for steroid-refractory graft versus host disease (SR-GvHD). Another key asset, PLX-R18, has completed Phase I clinical trials for incomplete hematopoietic recovery following hematopoietic cell transplantation and is being evaluated in animal studies for acute radiation syndrome. Pluristem has a license agreement for PLX-PAD clinical trials in South Korea and collaborates with NASA's Ames Research Center to explore PLX cell therapies for space-related medical conditions. The company also has a collaborative project, nTRACK, focused on gold nanoparticle labeling of stem cells.

What Products and Services Does PSTI Offer?

• Develop placental expanded (PLX) based cell therapy products.
• Conduct Phase III clinical trial for PLX-PAD for hip fracture recovery.
• Conduct Phase II clinical trial for PLX-PAD for acute respiratory distress syndrome associated with COVID-19.
• Conduct Phase I/II clinical trial for PLX-PAD for steroid-refractory graft versus host disease.
• Develop PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation.
• Conduct animal studies for PLX-R18 for the treatment of acute radiation syndrome.
• Collaborate with NASA to evaluate PLX cell therapies for space-related medical conditions.
• Conduct clinical trials of PLX-PAD product in South Korea through a license agreement.

How Does PSTI Make Money?

• Develop and commercialize cell therapy products.
• Generate revenue through licensing agreements.
• Secure funding through grants and collaborations.
• Potentially generate revenue through direct sales of approved therapies.

What Industry Does PSTI Operate In?

Pluristem Therapeutics operates within the biotechnology industry, a sector characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. Pluristem's focus on cell therapy places it within a rapidly evolving segment of the biotechnology market. Competitors are also developing cell-based therapies, creating a competitive landscape. The overall biotechnology market is projected to experience continued growth, driven by factors such as an aging population and increasing prevalence of chronic diseases.

Who Are PSTI's Key Customers?

• Patients suffering from ischemic conditions.
• Patients suffering from inflammatory conditions.
• Patients suffering from hematologic conditions.
• Patients suffering from autoimmune disorders.
• Hospitals and medical centers.

Company Profile

Pluristem Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Haifa, IL. The company is led by CEO Yaky Yanay. PSTI has traded publicly since 2007.

Return on equity for Pluristem Therapeutics Inc. stands at 79.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -65.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.33 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -101.3%, the inverse of the P/E and a quick read on earnings relative to price.

PSTI Valuation & Market Position

With a $40.9M market cap, Pluristem Therapeutics Inc. sits in the micro-cap segment of the market. Relative to its peer group, PSTI's quantitative score of 52/100 is roughly in line with the peer average of 59/100.

Quarterly Financial Performance: Pluristem Therapeutics Inc.

Revenue for Pluristem Therapeutics Inc. came in at $167K during Q1 2026, a 15.7% contraction versus the preceding quarter. The company recorded a net loss of $6.2M, with diluted EPS of $-0.55. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, PSTI averaged $-0.42 in diluted EPS.

Pluristem Therapeutics Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of -42.91 places it in the distress zone, a signal of elevated financial risk.

Pluristem Therapeutics Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 337.7% below estimates on average.

PSTI Financials

PSTI Latest News

No recent news available for PSTI.

PSTI Analyst Consensus

PSTI MoonshotScore

Common Questions About PSTI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources